Stay updated on Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial page.

Latest updates to the Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial page
- Check2 days agoChange DetectedThe page's revision tag was updated from v3.5.3 to v3.5.4. This signals a small update to the page metadata rather than changes to the study content.SummaryDifference0.0%

- Check9 days agoChange DetectedChanged the Age eligibility in the study to '18 Years and older' from the previous '18 Years to 120 Years', removing the upper age limit and expanding which adults may enroll in the trial.SummaryDifference0.2%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedChanges to the Chilean location listing replace regional labels in Spanish with corresponding region labels in English, while preserving the same locations and site identifiers (e.g., Temuco and Viña del Mar). The page revision/version string was updated accordingly.SummaryDifference0.5%

- Check60 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check74 days agoChange DetectedRevision: v3.4.3 has been added, replacing the previous Revision: v3.4.2.SummaryDifference0.0%

- Check95 days agoChange DetectedPage revision updated to v3.4.2, replacing the previous v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Immune-Target Combo in 2L+ Renal Cell Carcinoma Clinical Trial page.